1421 related articles for article (PubMed ID: 29444937)
1. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
2. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S
Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
5. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
6. HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.
Saleh S; Lu HK; Evans V; Harisson D; Zhou J; Jaworowski A; Sallmann G; Cheong KY; Mota TM; Tennakoon S; Angelovich TA; Anderson J; Harman A; Cunningham A; Gray L; Churchill M; Mak J; Drummer H; Vatakis DN; Lewin SR; Cameron PU
Retrovirology; 2016 Jul; 13(1):49. PubMed ID: 27459960
[TBL] [Abstract][Full Text] [Related]
7. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
8. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
9. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.
Martínez-Bonet M; Clemente MI; Álvarez S; Díaz L; García-Alonso D; Muñoz E; Moreno S; Muñoz-Fernández MÁ
Antiviral Res; 2015 Nov; 123():163-71. PubMed ID: 26427554
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
[TBL] [Abstract][Full Text] [Related]
12. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
13. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
14. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Painter MM; Zaikos TD; Collins KL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
[TBL] [Abstract][Full Text] [Related]
15. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
16. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.
Jiang G; Mendes EA; Kaiser P; Sankaran-Walters S; Tang Y; Weber MG; Melcher GP; Thompson GR; Tanuri A; Pianowski LF; Wong JK; Dandekar S
AIDS; 2014 Jul; 28(11):1555-66. PubMed ID: 24804860
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs
Pache L; Marsden MD; Teriete P; Portillo AJ; Heimann D; Kim JT; Soliman MSA; Dimapasoc M; Carmona C; Celeridad M; Spivak AM; Planelles V; Cosford NDP; Zack JA; Chanda SK
Cell Rep Med; 2020 Jun; 1(3):100037. PubMed ID: 33205060
[TBL] [Abstract][Full Text] [Related]
19. Naf1 Regulates HIV-1 Latency by Suppressing Viral Promoter-Driven Gene Expression in Primary CD4+ T Cells.
Li C; Wang HB; Kuang WD; Ren XX; Song ST; Zhu HZ; Li Q; Xu LR; Guo HJ; Wu L; Wang JH
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795436
[TBL] [Abstract][Full Text] [Related]
20. Transforming Growth Factor β Signaling Promotes HIV-1 Infection in Activated and Resting Memory CD4
Yim LY; Lam KS; Luk TY; Mo Y; Lu X; Wang J; Cheung KW; Lui GCY; Chan DPC; Wong BCK; Lau TT; Ngan CB; Zhou D; Wong YC; Tan Z; Liu L; Wu H; Zhang T; Lee SS; Chen Z
J Virol; 2023 May; 97(5):e0027023. PubMed ID: 37042759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]